ÀêóøåðñòâîÀíàòîìèÿÀíåñòåçèîëîãèÿÂàêöèíîïðîôèëàêòèêàÂàëåîëîãèÿÂåòåðèíàðèÿÃèãèåíàÇàáîëåâàíèÿÈììóíîëîãèÿÊàðäèîëîãèÿÍåâðîëîãèÿÍåôðîëîãèÿÎíêîëîãèÿÎòîðèíîëàðèíãîëîãèÿÎôòàëüìîëîãèÿÏàðàçèòîëîãèÿÏåäèàòðèÿÏåðâàÿ ïîìîùüÏñèõèàòðèÿÏóëüìîíîëîãèÿÐåàíèìàöèÿÐåâìàòîëîãèÿÑòîìàòîëîãèÿÒåðàïèÿÒîêñèêîëîãèÿÒðàâìàòîëîãèÿÓðîëîãèÿÔàðìàêîëîãèÿÔàðìàöåâòèêàÔèçèîòåðàïèÿÔòèçèàòðèÿÕèðóðãèÿÝíäîêðèíîëîãèÿÝïèäåìèîëîãèÿ

˲ÒÅÐÀÒÓÐÀ. [1] Ðîçðàõîâàíî ³ç çàñòîñóâàííÿ ÏÏ “ÑhemOffice 6.0 Pro” (free trial version)

Ïðî÷èòàéòå:
  1. VIII. ˳òåðàòóðà.
  2. Âèêîðèñòàíà ë³òåðàòóðà
  3. Äîäàòêîâà ë³òåðàòóðà
  4. ÄÎÄÀÒÊÎÂÀ ˲ÒÅÐÀÒÓÐÀ
  5. Äîäàòêîâà íàâ÷àëüíà ë³òåðàòóðà
  6. ˳òåðàòóðà
  7. ˳òåðàòóðà
  8. ˳òåðàòóðà
  9. ˲ÒÅÐÀÒÓÐÀ
  10. ˲ÒÅÐÀÒÓÐÀ

[1] Ðîçðàõîâàíî ³ç çàñòîñóâàííÿ ÏÏ “ÑhemOffice 6.0 Pro” (free trial version)


[1] Taylor J.L., Sabran J.L., Grossberg S.E. The cellular effects of interferon. Interferons and their applications. – Springer-Verlag, 1984.– P. 169 – 204.

[2] Ñïèâàê Í.ß. Àíòèáàêòåðèàëüíàÿ ýôôåêòèâíîñòü ïðåïàðàòîâ èíòåðôåðîíà è åãî èíäóêòîðîâ â ðàçëè÷íûõ áèîëîãè÷åñêèõ ñèñòåìàõ: Àâòîðåô. äèñ. … äîêò. áèîë. íàóê. – Ê., 1987. – 56 ñ.

[3] Ñï³âàê Ì.ß., Êàðïîâ Î,Â., Æîëîáàê Í.Ì. òà ³íø. // ̳êðîá³îë. Æóðí. – 2002. – Ò. 65, ¹ 1 – 2. – Ñ. 191 – 204.

[4] Maniatis T., Goodbourn S., Fischer J.A. // Science. – 1987. – Vol. 236. – P. 1237 – 1245.

[5] Taniguchi T. // Annu. Rev. Immunol. – 1988. – Vol. 6. – P. 439 – 464.

[6] Åðøîâ Ô.È. Ñèñòåìà èíòåðôåðîíà â íîðìå è ïàòîëîãèè. – Ì.: Ìåäèöèíà, 1996. – 240 ñ.

[7] Bendtzen K., Hansen M.B., Diamant M. et al // J. Interferon Res. – 1994. – Vol. 14. – P. 157 – 159.

[8] Ðàôàëüñêèé Â.Â. Êëèíè÷åñêîå ïðèìåíåíèå ïðåïàðàòîâ èíòåðôåðîíà. – Ñìîëåíñê: Ñìîëåíñêàÿ ãîñ. ìåä. àêàä., 1997. – 256 ñ.

[9] Bottomley J.M., Toy J.L. Clinical side effects and toxicities of interferon. / In: Interferon 4. In vivo and clinical studies. – ed. Friedman R.M. – Elsevier – Amsterdam–N.Y.–Oxford.– 1984.– P. 125 – 138.

[10] Biron C.A., Sen G.C. Interferon and other cytokines. / In D.M. Knipe, P. M. Howley, D.E. Griffin, M. Martin, B. Roizman and S.E. Straus (ed.), Fields virology, 4th ed. Lippincott-Raven, Philadelphia, Pa, 2001, P. 321 – 351.

[11] Ñïèâàê Í.ß., Ëàçàðåíêî Ë.Í., Ìèõàéëåíêî Î.Í. Èíòåðôåðîí è ñèñòåìà ìîíîíóêëåàðíûõ ôàãîöèòîâ. – Ê.: Ôèòîñîöèîöåíòð, 2002. – 164 ñ.

[12] Kontsek P., Karayianni-Vasconcelos G., Kontsekova E. // Acta Virol. – 2003. – Vol. 47. – P. 201 – 215.

[13] DeMayer E., DeMayer-Guignard J. Interferons and other regulatory cytokines. – New York: Wiley -Interscience, 1988. – 632 p.

[14] Cella M., Jarossay D., Facchetti F. et al // Nat. Med. – 1999. – Vol. 5. – P. 919 – 1003.

[15] Siegal F.P., Kadowaki N., Shodell M. et al // Science. – 1999. – Vol. 284. – P. 1835 – 1837.

[16] Ho M. Induction and inducers of interferon. / in Interferon 1. General and applied aspects, ed. A. Billiau – Elsevier-Amsterdam, N.Y., Oxford. – 1984. – P. 79 – 124.

[17] Marcus P. I. Interferon induction by viruses: double-stranded ribonucleuc acid as the common proximal inducer molecule. / in Interferon 3. Mechanisms of production and action, ed. Friedman R.M. – Elsevier-Amsterdam,N.Y.,Oxford. – 1984. – P. 113 – 175.

[18] De Clercq E. // Methods Enzymol. – 1981. – Vol. 78. – P. 227 – 243.

[19] Colby C, Chamberlin M.J. // Proc.Natl. Acad. Sci. USA. – 1969. – Vol. 63. – P. 160 – 167.

[20] Hutchinson D.W., Johnston M.D., Eaton M.A.V. // J. Gen. Virol. – 1974. – Vol. 23, ¹ 2. – P. 331 – 333.

[21] DeClercq E., Wells R.D., Grant R.C., Merigan T.C. // J. Mol. Biol. – 1971. – Vol. 56. – P. 83 – 100.

[22] Yamamoto S., Yamamoto T., Kataoka T. et al // J. Immunol. – 1992. – Vol. 148. – P. 4072 – 4076.

[23] Yamamoto T., Yamamoto S., Kataoka T. et al // Jpn. J. Cancer Res. – 1994. – Vol. 85. – P. 775 – 782.

[24] Krieg A.M., Yi A.K., Matson S. et al // Nature. – 1995. – Vol. 374. – P. 546 – 548.

[25] Bird A.P. // Trends Genet. – 1987. – Vol. 3. – P. 342 – 347.

[26] Medzhitov R., Janeway C., Jr. // Immunol. Rev. – 2000. – Vol. 173. – P. 89 – 97.

[27] Krieg A.M. // Curr. Opin. Immunol. – 2000. – Vol. 12. – P. 35 – 43.

[28] Kadowaki N., Antonenko S., Liu Y.-J. // J. Immunol. – 2001. – Vol. 166. – P. 2291 – 2295.

[29] DeSomer P., DeClercq E., Billiau A. et al // J. Virol. – 1968. – Vol. 2. – P. 886 – 893

[30] Albrecht W. L., Fleming H. W., Horgan S. W., Mayer G. D. // J. Med. Chem. – 1977. – Vol. 20. – P. 364 – 371.

[31] Glaz E.T., Szolgay E., Stoger I., Talas M. // Antimicrob. Agents Chemother. – 1973. – Vol. 3. – P. 537 – 544.

[32] Stringfellow D.A., Weed S.D., Underwood G.E. // Antimicrob. Agents Chemother. – 1979. – Vol. 15. – P. 111 – 118.

[33] Stringfellow D.A., Vanderberg H.C., Weed S.D. // J. Interferon Res. – 1980. – Vol. 1. – P. 1 – 16.

[34] Stringfellow D.A. Induction of interferon with low molecular weight compounds. / In: Interferons, Part A, Ed. S. Pestka, Methods in Enzymology – 1981 – Vol. 78.– Academ.Press, N.Y. – P. 262 – 284.

[35] Krueger R.F., Mayer G.D. // Science. – 1970. – Vol. 169. – P. 1213 – 1214.

[36] Mayer G.D., Krueger R.F. // Science. – 1970. – Vol. 169. – P. 1214 – 1215.

[37] Mayer G.D., Krueger R.F. Tilorone hydrochloride and related molecules. / In: “Interferon and interferon inducers”, Ed. Stringfellow D.A.; Dekker, New York,.– 1980.– P. 187 – 221.

[38] DeClercq E., Merigan T.C. // J. Infect. Dis. – 1971. – Vol. 123. – P. 190 – 199.

[39] Ãðèãîðÿí Ñ. Ñ., Åðøîâ Ô.È., Ïîâåðåííûé À.Ì. è äð.// Âîïðîñû âèðóñîëîãèè. – 1988. – Ò. 33, ¹ 1. – Ñ. 67 – 70.

[40] Stringfellow D.A. // Antimicrob. Agents Chemother. – 1977. – Vol. 11. – P. 984 – 992.

[41] Giron D.J., Schmidt J.P., Pindak F.F. // Antimicrob. Agents Chemother. – 1972. – Vol. 1. – P. 78 – 79.

[42] Ëÿõîâ Ñ.À. Àìèíîàëêîêñèôëóîðåíîíû: ñèíòåç è ñâîéñòâà. Äèñc. … êàíä. õèì. íàóê. Îäåññà, 1992. – 132 c.

[43] Ëÿõîâ Ñ. À., Ëèòâèíîâà Ë.À., Àíäðîíàòè Ñ. À., è äð.// Óêð. áèîõèì. æóðí. – 2001. – Ò. 74, ¹ 4. – Ñ. 108 – 113.

[44] Baccichetti F, Carlassare F, Bordin F et al // Farmaco. – 1980. – Vol. 35, ¹ 6. – P. 481 – 489.

[45] Šmejkal F., Zelena D., Krepelka J. // Acta Virol. – 1985. – Ò. 29. – P. 11 – 18.

[46] ×èæîâ Í.Ï., Áîðèñîâà Ì.À. // Àíòèáèîòèêè è ìåä. áèîòåõíîëîãèÿ. – 1987. – Ò. 32. – Ñ. 706 – 715.

[47] Ïàò. ÑØÀ 3692907 // http://www.uspto.gov/

[48] Ïàò. ÑØÀ 3592819 // http://www.uspto.gov/

[49] Ïàò. ÑØÀ 3576865 // http://www.uspto.gov/

[50] Ïàò. ÑØÀ 3983124 // http://www.uspto.gov/

[51] Ïàò. ÑØÀ 3647860 // http://www.uspto.gov/

[52] Ïàò. ÑØÀ 3662062 // http://www.uspto.gov/

[53] Ïàò. ÑØÀ 3814770 // http://www.uspto.gov/

[54] Ïàò. ÑØÀ 4064347 // http://www.uspto.gov/

[55] Alcaro S., Arena A., Neri S., et al // Bioorg. Med. Chem. – 2004. – Vol. 12, ¹ 7. – P. 1781 – 1791.

[56] Andrews E.R., Fleming R.W., Grisar J.M., et al // J. Med. Chem. – 1974. – Vol. 17. – P. 882 – 886.

[57] À.ñ. 1460926 (1988).ÑÑÑÐ // Á.È. – 1989. – ¹7.

[58] À.ñ. 963231 (1982).ÑÑÑÐ // Á.È. – 1982. – ¹36.

[59] Burke H.M., Joullie M.M. // J. Med. Chem. – 1978. – Vol. 21, ¹ 10. – P. 1084 – 1086

[60] Åðìîëüåâà Ç.Â., Êîðíååâà Ë.Â., Áàëåçèíà Ò. È. è äð.// Àíòèáèîòèêè. – 1973. – ¹ 5. – Ñ. 517 – 520.

[61] Áåðåçèíà Ë.Ê., Íîñèê Í.Í., Ëÿõîâ Ñ. À. è äð.// Èòîãè íàóêè è òåõíèêè. Ñåð. Âèðóñîëîãèÿ /ÂÈÍÈÒÈ. – Ì., 1991, 24. – Ñ. 78 – 79.

[62] Ïàò. 1264 (1993) Óêðàèíû // Á.È. – 1982. – ¹36.

[63] À.ñ. 1069355 (1983).ÑÑÑÐ // Á.È. – 1984. – ¹3.

[64] À.ñ. 1466225 (1988).ÑÑÑÐ // Á.È. – 1989. – ¹10.

[65] Íèêîëàåâà È.Ñ., Aäàìñêàÿ E.Â., Âîçÿêîâà Ò. È., Îëåéíèê À.Ô. // Õèì.-Ôàðì. Æóðí. – 1988. – Ò. 22, ¹ 8. – Ñ. 977 – 979.

[66] À.ñ. 946183 (1982).ÑÑÑÐ // Á.È. – 1982. – ¹27.

[67] Ïàò. 1315 (1994) Óêðàèíû // Á.È. – 1994. – ¹1.

[68] À.ñ. 1462728 (1988).ÑÑÑÐ // Á.È. – 1989. – ¹8.

[69] À.ñ. 725392 (1979).ÑÑÑÐ // Á.È. – 1979. – ¹12.

[70] À.ñ. 879920 (1981).ÑÑÑÐ // Á.È. – 1981. – ¹41.

[71] À.ñ. 1074082 (1983).ÑÑÑÐ // Á.È. – 1984. – ¹6.

[72] À.ñ. 1536753 (1989).ÑÑÑÐ // Á.È. – 1990. – ¹2.

[73] Ïàò. ÑØÀ 3932456 // http://www.uspto.gov/

[74] Ïàò. ÑØÀ 3962451 // http://www.uspto.gov/

[75] Ïàò. ÑØÀ 4146624 // http://www.uspto.gov/

[76] Ïàò. ÑØÀ 3952014 // http://www.uspto.gov/

[77] Ïàò. ÑØÀ 3933893 // http://www.uspto.gov/

[78] Ïàò. ÑØÀ 4169897 // http://www.uspto.gov/

[79] Ïàò. ÑØÀ 3953455 // http://www.uspto.gov/

[80] Ïàò. ÑØÀ 4059702 // http://www.uspto.gov/

[81] Ïàò. ÑØÀ 3957986 // http://www.uspto.gov/

[82] Ïàò. ÑØÀ 3957989 // http://www.uspto.gov/

[83] Ïàò. ÑØÀ 4008240 // http://www.uspto.gov/

[84] Ïàò. ÑØÀ 4048230 // http://www.uspto.gov/

[85] Niblack J.F. // Tex. ReP. Biol. Med. – 1977. – Vol. 35. – P. 528 – 534.

[86] Ïàò. ÑØÀ 4108896 // http://www.uspto.gov/

[87] Sill A.D., Andrews E.R., Sweet F.W. et al // J. Med. Chem. – 1974. – Vol. 17. – P. 965 – 968.

[88] Jamison J.M., Krabill K., Flowers D.G., Tsai C.C. // Cell Biol Int ReP. – 1990. – Vol. 14, ¹ 3. – P. 219 – 228

[89] Jamison J.M., Krabill K., Hatwalkar A. et al // Cell. Biol. Int. ReP. – 1990. – Vol. 14. – P. 1075 – 1084.

[90] Mayer G. D., Hagan A.C., Bray F. // Fed. Proc. – 1973. – Vol. 32. – P. 704.

[91] Ïàò. ÑØÀ 4021551 // http://www.uspto.gov/

[92] Ïàò. ÑØÀ 4696936 // http://www.uspto.gov/

[93] Lyakhov S.A., Suveyzdis Y.I., Berezina L.K. et al // Die Pharmazie. – 1994. – Vol. 49, ¹ 12. – P. 926 – 927.

[94] Lyakhov S.A., Suveyzdis Ya.I., Litvinova L.A. et al // Die Pharmazie. – 2000. – Vol. 55, ¹ 10. – P. 733 – 736.

[95] Ñóâåéçäèñ ß.È., Ëÿõîâ Ñ. À., Ëèòâèíîâà Ë.À. è äð.// Õèì.-ôàðì. æóðí. – 2000. – Ò. 34, ¹ 10. – Ñ. 15 – 16

[96] Ëÿõîâ Ñ. À., Ëèòâèíîâà Ë.À., Ñóâåéçäèñ ß.È. è äð. // Õèì.-ôàðì. æóðí. – 2000. – Ò. 34, ¹ 9. – Ñ. 20 – 21.

[97] Mucsi I, Molnar J, Tanaka M, Santelli-Rouvier C, Patelis AM, Galy JP, Barbe J. //Anticancer Res. – 1998. – Vol. 18, ¹ 4. – P. 3011 – 3015

[98] Diederich J., Lodemann E, Wacker A. // Naturwissenschaften – 1972. – Vol. 59. – P. 172 – 173.

[99] Diederich J., Lodemann E., Wacker A. // Arch. Ges. Virusforsch. – 1973. – Vol. 40. – P. 82 – 85.

[100] Angier R.B., Gitarella R.V., Damiani M., et al // J. Med. Chem. – 1983. – Vol. 26. – P. 1710 – 1715.

[101] Ïàòåíò ¹ 59034 À (2003) Óêðà¿íà // Á.Â. – 2003.– ¹ 8.

[102] Ïàòåíò ¹ 60793 À (2003) Óêðà¿íà // Á.Â. – 2003.– ¹ 10.

[103] Ëÿõîâ Ñ. À., Ëÿõîâà Å.À., Ïàí÷åíêî Í.Í., è äð. // Õèì.-ôàðì. æóðí. – 2001. – Ò. 35, ¹ 12. – Ñ. 10 – 13.

[104] Angier R.B., Gitarella R.V., Damiani M., et al // J. Med. Chem. – 1983. – Vol. 26. – P. 1710 – 1715.

[105] Szulc B., Inglot A.D., Szulc Z. Mlochowski J. // Arch. Immunol. Ther. ExP. – 1985. – Vol. 33. – P. 287 – 297.

[106] Inglot D. A., Mlochowski J., Szulc Z. et al // Arch. Immunol. Ther. ExP. – 1985. – Vol. 33. – P. 275 – 285.

[107] Kramer M.J., Cleeland R., Grunberg E. // Antimicrob. Agents Chemotherapy. – 1976. – Vol. 9. – P. 233 – 238.

[108] Storch E., Kirchner H. // Eur. J. Immunol. – 1982. – Vol. 12. – P. 793 – 796.

[109] Piasecki E., Inglot A.D., Czyrski J. A. et al. // Arch. Immunol. Ther ExP. – 1985. – Vol. 33. – P. 299 – 310.

[110] Szulc B., Szulc Z., Inglot A.D., et al // Antiviral Res. – 1987. – Vol. 7. – P. 109 – 117.

[111] Gaur V., Chandra P. // Naturwissenschaften. – 1973. – Vol. 60, ¹ 5. – P. 263.

[112] Gupta D.K., Gieselmann V., Hasilik A., von Figura K. // Hoppe-Seylers Z. Physiol. Chem. – 1984. – Vol. 365, ¹ 8. – P. 859 – 866.

[113] Êîâàëåíêî À.Ë., Êàçàêîâ Â.È., Ñëèòà À.Â. è äð. // Öèòîëîãèÿ. – 2000. – Ò. 42, ¹ 7. – Ñ. 659 – 664.

[114] Siminoff P., Bernard A.M., Hursky V.S., Price K.E. // Antimicrob. Agents Chemother. – 1973. – Vol. 3. – P. 742 – 751.

[115] Crenshaw R.R., Luke G.M., Siminoll P. // J. Med. Chem. – 1976. – Vol. 19. – P. 262 – 266.

[116] Gibson S.J., Imbertson L.M., Wagner T.L. et al // J. Interferon Cytokines Res. – 1995. – Vol. 15. – P. 537 – 545.

[117] Karaca K., Sharma J.M., Tamai M.A., Miller R.L. // J. Interferon Cytokines Res. – 1996. – Vol. 16. – P. 327 – 332.

[118] Ïàò. ÑØÀ 6348462 // http://www.uspto.gov/

[119] Ïàò. ÑØÀ 5525612 // http://www.uspto.gov/

[120] Ïàò. ÑØÀ 5482936 // http://www.uspto.gov/

[121] Ïàò. ÑØÀ 5346905 // http://www.uspto.gov/

[122] Ïàò. ÑØÀ 5268376 // http://www.uspto.gov/

[123] Ïàò. ÑØÀ 4689338 // http://www.uspto.gov/

[124] Reiter M.G., Testerman T.L., Miller R.L. et al // J. Leukoc. Biol. – 1994. – Vol. 55. – P. 214 – 220.

[125] Sidky Y.A., Borden E.C., Weeks C.E. et al // Cancer Res. – 1992. – Vol. 52. – P. 3528 – 3533.

[126] Wagner T.L., Harton V.L., Carlson G.L. et al // Cytokine. – 1997. – Vol. 9. – P. 637 – 845.

[127] Allison R.G., Hahn F.E. // Antimicrob. Agents Chemother. – 1977. – Vol. 11. – P. 251 – 257.

[128] Hahn E.F., Ciak J. // Antimicrob. Agents Chemother. – 1977. – Vol. 11. – P. 176 – 177.

[129] Nakada Y., Kosaka T., Kuwabara M. et al // J. Vet. Med. Sci. – 1993. – Vol. 55. – P. 795 – 799.

[130] Ikemoto K., Kobayashi M., Fukumoto T., et al // Experientia. – 1996. – Vol. 52. – P. 159 – 166.

[131] Õàèòîâè÷ À.Í., Ëüâîâñêèé Ý.À. // Âîïð. âèðóñîë. – 1975. – ¹ 2. – Ñ. 183 – 186.

[132] Lvovsky E., Levy H.B., Doherty D.G., Baron S. // Infect. Immun. – 1977. – Vol. 15. – P. 191 – 196.

[133] Hoffman W.W., Korst J.J., Niblack J.F., Cronin T.H. // Antimicrob. Agents Chemother. – 1973. – Vol. 3. – P. 498 – 501.

[134] Betts R.F., Douglas R.G. Interferon inducers: propanediamines and related molecules. / Interferon and interferon inducers, Ed. Stringfellow D.A.; Dekker, New York,.– 1980.– P. 223 – 237.

[135] Douglas R.G., Waldman R.H., Betts R.F., Ganguly R. // Antimicrob. Agents Chemother. – 1979. – Vol. 15. – P. 269 – 279.

[136] Tovey M.G., Begon-Lours J., Gresser I., Morris A.G. // Nature. – 1977. – Vol. 267. – P. 455 – 456.

[137] Vilèek J. Interferon production and its regulation. // Interferon 3. Mechanisms of production and action, ed. Friedman R.M. – Elsevier-Amsterdam, N.Y., Oxford.– 1984.– P. 1 – 10.

[138] Skulnick H.I., Weed S.D., Eidson E.E. et al // J.Med Chem. – 1985. – Vol. 28. – P. 1864 – 1869.

[139] Nichols F.R., Weed S.D., Underwood G.E. // Antimicrob. Agents Chemother. – 1976. – Vol. 9. – P. 433 – 446.

[140] Hirota K, Kazaoka K, Niimoto I, Sajiki H. // Org Biomol Chem. – 2003. – Vol. 1, ¹ 8. – P. 1354 – 1365. (Laboratory of Medicinal Chemistry, Gifu Pharmaceutical University, Mitahora-higashi, Gifu 502-8585, Japan. hirota@gifu-pu.ac.jp An efficient and general method for the synthesis of 2,9-disubstituted 8-hydroxyadenines, which are expected to have various biological activities, was realized. 5-Amino-4-cyano-2-hydroxyimidazoles(1) were prepared from aminomalononitrile and isocyanates as key intermediates. The condensation of 1a with amidines, imidates, guanidine, urea and thioureas afforded 8-hydroxyadenines (2-6) possessing various substituents at the 2-position. Furthermore, selective alkylation of 2-amino- and 2-hydroxyadenines (4 and 6) successively proceeded to give the corresponding 2-alkylamino- and 2-alkoxyadenines (5 and 7), respectively. 2-Alkylthioadenines (15) were prepared by an analogous reaction of 1a with benzoyl isothiocyanate and subsequent S-alkylation. The imidazoles 1 are most useful intermediates for the synthesis of 8-hydroxyadenine derivatives. PMID: 12929666)

[141] Kazaoka K., Sajiki H., Hirota K. // Chem. Pharm. Bull. – 2003. – Vol. 51 b. – P. 608 – 611.

[142] Hirota K, Kazaoka K, Sajiki H. // Bioorg Med Chem. – 2003. – Vol. 11, ¹ 13. – P. 2715 – 2722. Laboratory of Medicinal Chemistry, Gifu Pharmaceutical University, 5-6-1 Mitahora-higashi, Gifu 502-8585, Japan. hirota@gifu-pu.ac.jp Recently, we have identified 9-benzyl-8-hydroxyadenines bearing an appropriate substituent (a butoxy, propylthio or butylamino group) at the 2-position as potent interferon (IFN)-inducers. Herein we report the design, synthesis, and IFN-inducing activity of 8-substituted 9-benzyladenines possessing such an appropriate substituent at the 2-position. Introduction of the appropriate substituent into the 2-position of the adenine nucleus gave rise to expression of the activity even in 9-benzyladenines bearing no hydroxyl group at the 8-position. An amino group at the 6-position and a hydroxyl or thiol group carrying an acidic proton at the 8-position are required to express excellent IFN-inducing activity. 9-Benzyl-2-butoxy-8-mercaptoadenine (9) indicated the most potent activity with MEC of 0.001 microM. PMID: 12788345)

[143] Hirota K, Kazaoka K, Niimoto I. et al // J Med Chem. – 2002. – Vol. 45, ¹ 25. – P. 5419 – 5422 (Laboratory of Medicinal Chemistry, Gifu Pharmaceutical University, Mitahora-higashi, Gifu 502-8585, Japan. hirota@gifu-pu.ac.jp 9-Benzyl-8-hydroxyadenine (6) was found to possess interferon-inducing activity in vitro as a lead compound. Although replacement of the 9-benzyl group of 6 did not improve the activity, the introduction of a substituent such as alkyl, alkylthio, alkylamino, and alkoxy groups into the 2-position of the adenine ring resulted in a remarkable increase in the activity. The 2-alkylthio (30-32), 2-butylamino (41), and 2-butoxy (47) analogues indicated the highest activities by oral administration to mice. PMID: 12459008).

[144] Dorsch H.-M., Osundwa V., Lam P. // Immunol.Lett. – 1988. – Vol. 17. – P. 125 – 132.

[145] Koo G.C., Jewell M.E.., Manyak C.L. // J. Immunol. – 1988. – Vol. 140. – P. 3249 – 3252.

[146] Smee D.F., Alaghamandan H.A., Cottam H.B. et al // Antimicrob. Agents Chemotherapy. – 1989. – Vol. 33. – P. 1487 – 1492.

[147] Ãëóøêîâ P.Ã., Ãóñüêîâà Ò.À., Êpûëîâà Ë.Þ., è äð. // Âåñòí. Ðîññ. Àêàä. Ìåä. Íàóê. – 1999. – ¹ 3. – Ñ. 36 – 40.

[148] Fikus M., Golas T., Inglot A. D. et al // Chem. Biol. Interactions – 1987. – Vol. 62. – P. 25 – 43.

[149] Balkwill F.R. // Lancet. – 1989. – ¹ 8646. – P. 1060 – 1063.

[150] Chandra P., Wright G.S. // Current. Med. Chem. – 1977. – Vol. 12. – P. 125 – 148.

[151] Wright R.G., Wakelin L.P. G., Fieldes A. et al // Biochemistry. – 1980. – Vol. 19. – Ð. 5825 – 5836.

[152] Ëèòâèíîâà Ë.À., Ëÿõîâ Ñ. À. – Äåï. ÂÈÍÈÒÈ ¹ 6264-Â89 (Ôèçèêî-õèìè÷åñêèé èíñòèòóò ÀÍ ÓÑÑÐ). – Îä., 1989. – 13 c.

[153] Êàðïîâ Î.Â. // Óêð. áèîõèì. æóðí. – 1997. – Ò. 69. – Ñ. 122 – 125.

[154] Êàðïîâ Î.Â. // Óêð. áèîõèì. æóðí. – 1997. – Ò. 69. – Ñ. 49 – 52.

[155] Êàðïîâ À.Â., Æîëîáàê Í.Ì. // Àíòèáèîòèêè è õèìèîòåðàïèÿ. – 1995. – T.40. – C. 20 – 23.

[156] Êàðïîâ À.Â., Æîëîáàê Í.Ì. // Âîïð.âèðóñîë. – 1996. – Ò. 41. – Ñ. 13 – 16.

[157] Êàðïîâ À.Â., Àíòîíåíêî Ñ. Â. Áàðáàøåâà Å.Â., Ñïèâàê Í.ß. // Âîïð.âèðóñîë. – 1997. – Ò. 42. – Ñ. 17 – 19.

[158] Karpov A.V., Zholobak N.M., Spivak N.Ya. et al // Acta Virologica. – 2001. – Vol. 45. – P. 181 – 184.

[159] Karpov A.V. // Áèîïîëèìåðû è êëåòêà. – 1998. – Ò. 14. – Ñ. 1 – 6.

[160] Ëèòâèíîâà Ë.À., Ëÿõîâ Ñ. À., Àíäðîíàòè Ñ. À. è äð. // Õèì.-ôàðì. æóðí. – 2000. – Ò. 27, ¹ 12. – Ñ. 35 – 37.

[161] Êàðïîâ À.Â., Æîëîáàê Í.Ì. Èíòåðôåðîíîãåííûå ñâîéñòâà êîìïëåêñà äðîææåâàÿ ÐÍÊ – òèëîðîí â êóëüòóðå êëåòîê // Àíòèáèîòèêè è õèìèîòåð. – 1995. – Ò. 5. – Ñ. 20 – 23.

[162] Lyakhov S.A. Abstract book of 6th international Symposium on molecular aspects of chemoterapy, 9 – 12 July 1997. – Gdansk, Poland, P. 137.

[163] Field A.K., Tytell A.A., Lampson G.R., Hilleman M.R. // Proc. Natl. Acad. Sci. USA. – 1967. – Vol. 58. – P. 1004 – 1010.

[164] Green J.J., Alderfer J.L., Tazawa I. et al // Biochemistry. – 1978. – P. 4214 – 4220.

[165] Agrawal S., Goodchild J., Civeira M.P. et al. // Proc Natl. Acad. Sci. USA. – 1988. – Vol. 85, ¹ 19. – P. 7079 – 7083.

[166] Loke S.I., Stein C.A., Zhang X.H. et al. // Proc. Natl. Acad. Sci. USA. – 1989. – Vol. 86, ¹ 10. – P. 3474 – 3478.

[167] Yakubov L.A., Deeva E.A., Zarytova V.F. et al. // Proc. Natl. Acad. Sci. USA. – 1989. – Vol. 86. – P. 6454 – 6458.

[168] Lemaitre B., Nicolas E., Michaut L. et al // Cell. – 1996. – Vol. 86. – P. 973 – 986.

[169] Medzhidov R., Preston– Hurburt P., Janeway C., Jr. // Nature. – 1997. – Vol. 388. – P. 394 – 397.

[170] Akira S. // Curr. Opin. Immunol. – 2003. – Vol. 15. – P. 5 – 11.

[171] Akira S., Hemmi H. // Immunol. Let. – 2003. – Vol. 85. – P. 85 – 95.

[172] Medzhidov R., Janeway C., Jr. // N.Engl. J. Med. – 2000. – Vol. 343. – P. 338 – 344.

[173] Aderem A., Ulevitch R.J. // Nature. – 2000. – Vol. 406. – P. 782 – 787.

[174] Wagner H. // Immunity. – 2001. – Vol. 14. – P. 499 – 502.

[175] Matsumoto M., Funami K., Oshiumi H., Seya T. // Microbiol. Immunol. – 2004. – Vol. 48. – P. 147 – 154.

[176] O’Neil L.A.J., Dinarello C.A. // Immunol. Today. – 2000. – Vol. 21. – P. 206 – 209.

[177] Ñampos M.A., Almeida I.C., Takeuchi O. et al // J. Immunol. – 2001. – Vol. 167. – P. 416 – 423.

[178] Underhill D.M., Ozinsky A., Hajjar A.M. et al // Nature. – 1999. – Vol. 401. – P. 811 – 815.

[179] Alexopoulou L., Holt A.C., Medzhitov R., Flavell R.A. // Nature. – 2001. – Vol. 413. – P. 732 – 738.

[180] Poltorak A., He X., Smirnova I. et al // Science. – 1998. – Vol. 282. – P. 2085 – 2088.

[181] Hayashi F., Smith K.D., Ozinsky A. et al // Nature. – 2001. – Vol. 410. – P. 1099 – 1103.

[182] Hemmi H., Kaisho T., Takeuchi O. et al // Nat. Immunol. – 2002. – Vol. 3. – P. 196 – 200.

[183] Bauer S., Kirschning C.J., Hacker H. et al // Proc. Natl. Acad. Sci. USA. – 2001. – Vol. 98. – P. 9237 – 9242.

[184] Diebold S.S., Kaisho T., Hemmi H. et al // Science. – 2004. – Vol. 303. – P. 1529 – 1531.

[185] Takeda K., Kaisho T., Akira S. // Ann. Rev. Immunol. – 2003. – Vol. 21. – P. 335 – 373.

[186] Kawai T., Takeuchi O., Fujita T. et al // J. Immunol. – 2001. – Vol. 167. – P. 5887 – 5894.

[187] Horng T., Barton G.M., Medzhitov R. // Nat. Immunol. – 2001. – Vol. 2. – P. 835 – 841.

[188] Oshiumi H., Matsumoto M., Funami K. et al // Nat. Immunol. – 2003. – Vol. 4. – P. 161 – 167.

[189] Òèìîøîê Í.Î. Àíòèáàêòåð³àëüíà åôåêòèâí³ñòü ³íäóêòîð³â ³íòåðôåðîíó ð³çíîãî ïîõîäæåííÿ: Àâòîðåô. äèñ.... êàíä. á³îë. íàóê. – Ê., 2002. – 21 ñ.

[190] Ìàëàøåíêîâà È.Ê., Òàçóëàõîâà Ý.Á. // Òåð. Àðõèâ. – 1998. – ¹ 11. – Ñ. 35 – 39.

[191] Ïîäãîðñêèé Â.Ñ., Êîâàëåíêî Ý.À., Ñèìîíåíêî È.À. Ëåêòèíû áàêòåðèé – Ê.: Íàóêîâà äóìêà, 1992. – 200 c.

[192] Spivak N. Ya., Grabchenko N.I., Lazarenko L.N. et al // Íàóêîâèé â³ñíèê Óæãîðîäñüêîãî äåðæàâíîãî óí³âåðñèòåòó. Ñåð³ÿ: Á³îëîã³ÿ. – 2000. – ¹ 8. – Ñ. 10 – 13.

[193] Åðøîâ Ô.È. Àíòèâèðóñíûå ïðåïàðàòû. – Ì.: Ìåäèöèíà, 1998. – 187 ñ.

[194] Tanaka H., Samuel C.E. // Proc. Natl. Acad. Sci. USA. – 1994. – Vol. 91. – P. 7995 – 7999.

[195] Staeheli P. Interferon– induced proteins and the antiviral state. // Adv. Virus. Res. – 1990. – Vol. 38. – P. 147 – 200.

[196] Schumacher B., Bernasconi D., Schultz U., Staeheli P. // Virology. – 1994. – Vol. 203.– P. 144 – 148.

[197] Karupiah G., Xie Q.W., Buller R.M., Nathan C., Duarte C., MacMicking J.D. // Science. – 1993. – Vol. 261. – P. 1445 – 1448.

[198] Alber D., Staeheli P. // J. Interferon Cytokine Res. – 1996. – Vol. 16. – P. 375 – 381.

[199] Samuel C.E. // Curr. ToP. Microbiol. Immunol. – 1998. – Vol. 233. – P. 125 – 145.

[200] Samuel C.E. // Clin. Microbiol. Rev. – 2001. – Vol. 14. – P. 778 – 809.

[201] Proud C.G. // Trends Biochem. Sci. – 1995. – Vol. 20. – P. 241 – 246.

[202] Muto N.F., Martinand– Mari C., Adelson M.E., Suhadolnik R.J. // J. Virol. – 1999. – Vol. 73. – P. 9021 – 9028.

[203] Bass B.L., Weintraub H. // Cell. – 1988. – Vol. 55. – P. 1089 – 1098.

[204] Wagner R.W., Smith J.E., Cooperman B.S., Nishikura K. // Proc. Natl. Acad. Sci, USA. – 1989. – Vol. 86. – P. 2647 – 2651.

[205] Jacobs B.L., Langland J.O. // Virology. – 1996. – Vol. 219. – P. 339 – 349.

[206] Chandra P., Zunino F., Götz A. // FEBS Lett. – 1972. – Vol. 22. – P. 161 – 164.

[207] Chandra P., Will G., Gericke D., Götz A. // Biochem. Pharmacol. – 1974. – Vol. 23. – P. 3259 – 3265.

[208] Åðøîâ Ô.È., Òàçóëàõîâà Ý.Á. // Âîïð. âèðóñîë. – 1999. – Ò. 44. – Ñ. 52 – 56.

[209] Çåìñêîâ À.Ì., Ïåðåäåðèé Â.Ã., Çåìñêîâ Â.Ì., Áû÷êîâà Í.Ã. Èììóíîêîððåãèðóþùèå íóêëåèíîâûå ïðåïàðàòû è èõ êëèíè÷åñêîå ïðèìåíåíèå. – Ê.: Çäîðîâ’ÿ, 1994. – 228 ñ.

[210] Àíäðîíàòè Ñ. À., Ëèòâèíîâà Ë.À., Ãîëîâåíêî Í.ß. // Æóðí. Àêàä. ìåä. íàóê Óêðàèíû. – 1999. – T. 5, ¹ 1. – C. 53 – 66.

[211] Zheng Z.M., Mayo D.R., Fong C.K. et al // Intervirology. – 1985. – Vol. 23. – P. 44 – 50.


Äàòà äîáàâëåíèÿ: 2015-09-27 | Ïðîñìîòðû: 669 | Íàðóøåíèå àâòîðñêèõ ïðàâ







Ïðè èñïîëüçîâàíèè ìàòåðèàëà ññûëêà íà ñàéò medlec.org îáÿçàòåëüíà! (0.034 ñåê.)